Bookmark

Products

Pipeline highlight

View our product pipeline

AS1409

Untitled Document

AS1409 (huBC1-huIL12)

AS1409 is a fusion protein combining the anti-tumour cytokine IL-12, with the tumour-targeting antibody BC1. A phase I trial with AS1409 in patients with malignant melanoma and renal cell carcinoma has been completed.

Latest presentations

AS1409 phase I study poster presentation at ASCO Orlando 2009 (PDF, 816 KB, opens a new browser window)
Melanoma and renal cancer preclinical poster presentation at AACR Los Angeles 2007 (PDF, 2.45 MB, opens a new browser window)

huBC1 binds to a fibronectin splice variant (ED-B) that is highly expressed in the extracellular matrix and blood vessels of tumour tissues but has very restricted distribution in normal tissues.

IL-12 is a cytokine with both cytotoxic and anti-angiogenic activity that has demonstrated anti-cancer effects in clinical trials with renal cancer and melanoma patients. However, the systemic application of IL-12 has been limited by its toxicity.

AS1409 is designed to deliver IL-12 directly to the tumour vasculature via the antibody BC1 and to evoke a localised immune cascade, whilst minimising the systemic side effects of IL-12.